Morning Brief: Top Financial Stories Dominating on Wednesday, May 18 CNBC Toyota Looks To Develop Hydrogen Mobility In Europe Benzinga · May 18, 2022
Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge. Benzinga · May 18, 2022
India’s ‘other’ COVID vaccines: The status of under-trial, approved and unused jabs While Covishield and Covaxin lead the Covid-19 vaccination effort in India, other vaccines, too, are under development or remain unused after approval from the Centre The Hindu · May 18, 2022
Vic institute to tackle neglected diseases Victoria's Burnet Institute has partnered with Moderna to develop new vaccines for diseases such as malaria and hepatitis C. AAP · May 17, 2022
Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 105.44% on an annualized basis producing an average annual return of 116.6%. Currently, Moderna has a market capitalization of $56.68 billion. Benzinga · May 17, 2022
Moderna And 3 Other Stocks Insiders Are Selling US crude oil futures traded lower, dropping around 0.5% on Monday. Investors, meanwhile, focused on some notable insider trades. Benzinga · May 16, 2022
Morning Brief: Top Financial Stories Dominating on Monday, May 16 CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market Benzinga · May 16, 2022
Australia risks relying on Pfizer and Moderna for its COVID vaccines. 3 ways to break free The rapid development and deployment of COVID vaccines has been one of the greatest achievements of the pandemic. The Conversation · May 15, 2022
Biden administration and GOP clash over vaccine strategy The administration wants to keep access as open as possible, but the GOP wants to reduce wastage. Axios · May 12, 2022
Why Did Moderna CFO Exit Just A Day After Taking Charge Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to… Benzinga · May 11, 2022
Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52. Benzinga · May 10, 2022
Fourth Covid booster vaccine 'significantly' improves protection over just three jabs It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research. Daily Record · May 10, 2022
Covid vaccines safe for pregnant women and cut stillbirth risk, says review Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women The Guardian - UK · May 10, 2022
Fourth booster ‘significantly’ increases Covid protection Levels of antibodies waned in period between third jabs and fourth boosters Wales Online · May 10, 2022
The Independent UK · May 9, 2022 Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab
Benzinga · May 9, 2022 Morning Brief: Top Financial Stories Dominating on Monday, May 9 CNBC Ford Motor Selling 8M Shares Of Rivian Automotive
Benzinga · May 9, 2022 Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.
Benzinga · May 6, 2022 Looking At Moderna's Recent Whale Trades Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Asharq Al-Awsat · May 6, 2022 US Drug Regulator Limits Use of J&J Covid Vaccine The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…
Benzinga · May 5, 2022 Check Out What Whales Are Doing With MRNA Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Benzinga · May 5, 2022 Where Moderna Stands With Analysts Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:
Los Angeles Times · May 5, 2022 Commentary: COVID won’t become endemic until we have a vaccine for kids under 5 Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…
Benzinga · May 4, 2022 Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Benzinga · May 4, 2022 Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.
The Conversation · May 4, 2022 Will new vaccines be better at fighting coronavirus variants? 5 questions answered The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…